Samrat Pharmachem Ltd. exhibits significant underperformance across key financial metrics compared to its peers, particularly in growth and profitability. However, its low PE ratio presents it as a potential value pick for investors willing to take on higher risk. Among its peers, companies like Cipla and Dr. Reddy's Laboratories stand out as strong performers in profitability and growth.

• • Samrat Pharmachem shows zero revenue growth and earnings, indicating stagnation.
• • Cipla leads with a 13.28% YoY revenue growth and a solid EPS of 66.76.
• • Dr. Reddy's and Mankind Pharma demonstrate strong profitability metrics with high ROE and margins.
• • Sun Pharmaceutical Industries is significantly overvalued with a high PE of 87.59 despite decent growth.
• • Financially, Samrat Pharmachem presents a low debt equity ratio, which is a positive signal.